Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1992-10-15
|
pubmed:abstractText |
The risk of developing a chronic carriage state after acute hepatitis B infection in adults was evaluated. Two hundred and eighty-nine HBV-susceptible heterosexual partners of acute hepatitis B patients were used to investigate the effectiveness of post-exposure immunoprophylaxis; 75 of them received hepatitis B vaccine, 72 hepatitis B hyperimmune globulin (HBIG), 71 vaccine plus HBIG and 71 placebo. Participants were interviewed, clinically examined and serum specimens were taken at 1, 3, 6 and 9 months after their first intervention. Serum samples were tested for ALT and HBV markers (HBsAg, anti-HBc and anti-HBs) using radio immunoassays. Forty-six (15.9%) of the heterosexual partners examined were infected; the incidence of HBV infections was higher among placebo (18.3%, 13/71) and HBIG (18.1%, 13/72) recipients compared to vaccine (16.0%, 12/75) and HBIG plus vaccine (11.3%, 8/71) recipients, but the differences were not statistically significant. Infections were significantly more often subclinical after immunoprophylaxis (p = 0.03). HBsAg was detected in all eight clinical and in 13 of the 38 subclinical cases. In the remaining 25 subclinical cases HBV infections were diagnosed by the development of anti-HBc and anti-HBs during the follow-up period. Finally, all 46 cases studied cleared the HBsAg.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Hepatitis Vaccines
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-8126
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
221-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1387866-Acute Disease,
pubmed-meshheading:1387866-Adolescent,
pubmed-meshheading:1387866-Adult,
pubmed-meshheading:1387866-Carrier State,
pubmed-meshheading:1387866-Chronic Disease,
pubmed-meshheading:1387866-Combined Modality Therapy,
pubmed-meshheading:1387866-Female,
pubmed-meshheading:1387866-Hepatitis B,
pubmed-meshheading:1387866-Hepatitis B Antibodies,
pubmed-meshheading:1387866-Hepatitis B Surface Antigens,
pubmed-meshheading:1387866-Hepatitis B Vaccines,
pubmed-meshheading:1387866-Humans,
pubmed-meshheading:1387866-Immunoglobulins, Intravenous,
pubmed-meshheading:1387866-Incidence,
pubmed-meshheading:1387866-Male,
pubmed-meshheading:1387866-Prospective Studies,
pubmed-meshheading:1387866-Sexual Partners,
pubmed-meshheading:1387866-Viral Hepatitis Vaccines
|
pubmed:articleTitle |
Chronic liver disease rarely follows acute hepatitis B in non-immunocompromised adults.
|
pubmed:affiliation |
National Centre for Viral Hepatitis, Athens School of Hygiene, Greece.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|